Case report: Concurrent intrathecal and intravenous pembrolizumab for metastatic melanoma with leptomeningeal disease
Leptomeningeal disease (LMD) is a serious cancer complication associated with poor prognosis. Approximately 5%–25% of patients with melanoma develop LMD. Currently, no standard treatment protocol exists and very few cases have been reported. Despite ongoing advances in new therapies, treatment optio...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1344829/full |
| _version_ | 1827288033593917440 |
|---|---|
| author | Xiang Dan Mengxi Huang Zhaochen Sun Zhaochen Sun Xiaoyuan Chu Xin Shi Yitian Chen |
| author_facet | Xiang Dan Mengxi Huang Zhaochen Sun Zhaochen Sun Xiaoyuan Chu Xin Shi Yitian Chen |
| author_sort | Xiang Dan |
| collection | DOAJ |
| description | Leptomeningeal disease (LMD) is a serious cancer complication associated with poor prognosis. Approximately 5%–25% of patients with melanoma develop LMD. Currently, no standard treatment protocol exists and very few cases have been reported. Despite ongoing advances in new therapies, treatment options for LMD remain limited. Herein, we report a case of intrathecal pembrolizumab administration in a patient with melanoma and LMD. Intrathecal pembrolizumab administration was feasible and safe at the doses tested. Drawing from this case, along with our expertise and the existing evidence on systemic immunotherapy, we propose that an immunotherapy approach involving intrathecal administration for patients with LMD from melanoma warrants additional exploration in clinical trials. |
| first_indexed | 2024-04-24T11:22:59Z |
| format | Article |
| id | doaj.art-f0834991576d4336a47fe5c576905019 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-24T11:22:59Z |
| publishDate | 2024-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-f0834991576d4336a47fe5c5769050192024-04-11T04:34:01ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-04-011410.3389/fonc.2024.13448291344829Case report: Concurrent intrathecal and intravenous pembrolizumab for metastatic melanoma with leptomeningeal diseaseXiang Dan0Mengxi Huang1Zhaochen Sun2Zhaochen Sun3Xiaoyuan Chu4Xin Shi5Yitian Chen6Affiliated Jinling Hospital, School of Medicine, Nanjing University, Nanjing, ChinaDepartment of Medical Oncology, Affiliated Jinling Hospital, School of Medicine, Nanjing University, Nanjing, ChinaAffiliated Jinling Hospital, School of Medicine, Nanjing University, Nanjing, ChinaDepartment of Medical Oncology, Affiliated Jinling Hospital, School of Medicine, Nanjing University, Nanjing, ChinaDepartment of Radiation Oncology, Affiliated Jinling Hospital, School of Medicine, Nanjing University, Nanjing, ChinaDepartment of Orthopedics, Jinling Hospital, Nanjing, ChinaDepartment of Medical Oncology, Affiliated Jinling Hospital, School of Medicine, Nanjing University, Nanjing, ChinaLeptomeningeal disease (LMD) is a serious cancer complication associated with poor prognosis. Approximately 5%–25% of patients with melanoma develop LMD. Currently, no standard treatment protocol exists and very few cases have been reported. Despite ongoing advances in new therapies, treatment options for LMD remain limited. Herein, we report a case of intrathecal pembrolizumab administration in a patient with melanoma and LMD. Intrathecal pembrolizumab administration was feasible and safe at the doses tested. Drawing from this case, along with our expertise and the existing evidence on systemic immunotherapy, we propose that an immunotherapy approach involving intrathecal administration for patients with LMD from melanoma warrants additional exploration in clinical trials.https://www.frontiersin.org/articles/10.3389/fonc.2024.1344829/fullleptomeningeal diseasemetastatic melanomapembrolizumabcancerimmunotherapy |
| spellingShingle | Xiang Dan Mengxi Huang Zhaochen Sun Zhaochen Sun Xiaoyuan Chu Xin Shi Yitian Chen Case report: Concurrent intrathecal and intravenous pembrolizumab for metastatic melanoma with leptomeningeal disease Frontiers in Oncology leptomeningeal disease metastatic melanoma pembrolizumab cancer immunotherapy |
| title | Case report: Concurrent intrathecal and intravenous pembrolizumab for metastatic melanoma with leptomeningeal disease |
| title_full | Case report: Concurrent intrathecal and intravenous pembrolizumab for metastatic melanoma with leptomeningeal disease |
| title_fullStr | Case report: Concurrent intrathecal and intravenous pembrolizumab for metastatic melanoma with leptomeningeal disease |
| title_full_unstemmed | Case report: Concurrent intrathecal and intravenous pembrolizumab for metastatic melanoma with leptomeningeal disease |
| title_short | Case report: Concurrent intrathecal and intravenous pembrolizumab for metastatic melanoma with leptomeningeal disease |
| title_sort | case report concurrent intrathecal and intravenous pembrolizumab for metastatic melanoma with leptomeningeal disease |
| topic | leptomeningeal disease metastatic melanoma pembrolizumab cancer immunotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1344829/full |
| work_keys_str_mv | AT xiangdan casereportconcurrentintrathecalandintravenouspembrolizumabformetastaticmelanomawithleptomeningealdisease AT mengxihuang casereportconcurrentintrathecalandintravenouspembrolizumabformetastaticmelanomawithleptomeningealdisease AT zhaochensun casereportconcurrentintrathecalandintravenouspembrolizumabformetastaticmelanomawithleptomeningealdisease AT zhaochensun casereportconcurrentintrathecalandintravenouspembrolizumabformetastaticmelanomawithleptomeningealdisease AT xiaoyuanchu casereportconcurrentintrathecalandintravenouspembrolizumabformetastaticmelanomawithleptomeningealdisease AT xinshi casereportconcurrentintrathecalandintravenouspembrolizumabformetastaticmelanomawithleptomeningealdisease AT yitianchen casereportconcurrentintrathecalandintravenouspembrolizumabformetastaticmelanomawithleptomeningealdisease |